Janine Thomas
Investor Relations
Replay available
Moleculin Biotech, Inc. (NASDAQ: MBRX) Q3 2024 earnings conference call, held 2024-11-11. Replay captured from the company's public earnings webcast.

Investor Relations
Senior Chief Medical Officer
Executive Vice President and Chief Financial Officer
Analyst, Rawlton
Analyst, H.C. Wainwright
Greetings and welcome to the Molecular and Biotech Quarterly Update Conference Call and Webcast. At this time, all participants are in listen-only mode. If anyone should require operator assistance, please press star zero on your telephone keypad. A question and answer session will follow the formal presentation. You may be placed into question queue at any time by pressing star one on your telephone keypad. As a reminder, this conference is being recorded. It's now my pleasure to introduce your host, Janine Thomas, Investor Relations. Please go ahead, Janine. Thank you, Kevin. Good morning and welcome, everyone. At this time, I would like to remind our listeners that remarks made during this webcast may state management's intentions, beliefs, expectations, or future projections. These are forward-looking statements and involve risks and uncertainties. Forward-looking statements on this call are made pursuant to the safe harbor provisions of the Federal Securities Laws and are based on Moleculin's current expectations, and actual results could differ materially. As a result, you should not place undue reliance on any forward-looking statements. Some of the factors that could cause actual results to differ materially from these contemplated by such forward-looking statements are discussed in the periodic reports Moleculin files with the Securities and Exchange Commission. These documents are available in the Investors section of the company's website and on the Securities and Exchange Commission's website. We encourage you to review these documents carefully. Additionally, certain information contained in this webcast relates to or is based on studies, publications, surveys, and other data obtained from third-party sources and the company's own estimates and research....